Eli Lilly Submitting sNDA for Cymbalta to Treat Fibromyalgia

Washington Drug Letter
A A
Eli Lilly has submitted a supplemental new drug application (sNDA) to the FDA for its antidepressant Cymbalta to manage fibromyalgia, the company announced.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00